P/B
15,4
Amylyx Pharmaceuticals
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.
$3.7B
Market Cap • 9/22/2026
2014
(12 years)
Founded
2022
(4 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
—
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
2,3
EPS
—
Market Cap
Market Cap
3,7B
EV
3,4B
EV/Revenue
0
EV/EBITDA
-21,2
EV/EBIT
-21,2
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-0,3%
Total Yield
-0,3%
Payout
0%
Retained Earnings
-836,1M
Profitability
Gross Margin
—
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
0%
Capex/Revenue
0%
Capex/D&A
37,9%
Capex/OCF
-0,1%
SBC/OCF
—
% PPE
1,8%
% Goodwill
0%
ROE
—
ROIC
—
Leverage
N.D./EBITDA
1,5
Debt/Equity
0%
Current Ratio
12,1
Quick Ratio
11,9
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!